【国投证券 | 医药】新药周观点:映恩B7H3 ADC展现mCRPC领域BIC潜力,后续多个二代IO+ADC数据读出值得期待

国投证券医药研究
Mar 08

摘要本周新药行情回顾:2026年3月2日-2026年3月8日,新药板块涨幅前5:亚虹医药(+38.11%)、药捷安康(+33.53%)、德琪医药(+19.57%)、开拓药业(+8.58%)、荣昌生物(+7.33%);跌幅前5:永泰生物(-14.23%)、友芝友(-21.27%)、科济药业(-23.13%)、轩竹生物(-24.24%)、宝济药业(-34.54%)。本周建议关注标的:考虑板块后续仍有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10